Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
NCT ID: NCT00479492
Last Updated: 2009-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
94 participants
INTERVENTIONAL
2007-06-30
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
NCT00367783
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
NCT04010786
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
NCT00396448
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
NCT00494767
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
NCT03661879
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CP-866,087
1 mg of CP-866,087, administered QD for 84 days
2
CP-866,087
5 mg of CP-866,087, administered QD for 84 days
3
CP-866,087
10 mg of CP-866,087, administered QD for 84 days
4
placebo
placebo administered QD for 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-866,087
1 mg of CP-866,087, administered QD for 84 days
CP-866,087
5 mg of CP-866,087, administered QD for 84 days
CP-866,087
10 mg of CP-866,087, administered QD for 84 days
placebo
placebo administered QD for 84 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Otherwise healthy
Exclusion Criteria
* Significant current or history of medical illness.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5051019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.